(Q38985492)

8 September 2017

Physiological normal levels of androgen inhibit proliferation of prostate cancer cells in vitro (English)

1 reference

8 September 2017

1 reference

Weitao Song

1

1 reference

PMCID

4236330

8 September 2017

Mohit Khera

series ordinal

2

1 reference

8 September 2017

1 November 2014

1 reference

Asian Journal of Andrology

8 September 2017

1 reference

8 September 2017

16

1 reference

8 September 2017

6

1 reference

8 September 2017

864-868

1 reference

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer

8 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Testosterone therapy and prostate carcinoma

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Survival following primary androgen deprivation therapy among men with localized prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Testosterone therapy for men at risk for or with history of prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

LNCaP model of human prostatic carcinoma.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Low serum testosterone levels are associated with positive surgical margins in radical retropubic prostatectomy: hypogonadism represents bad prognosis in prostate cancer

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Hormonal predictors of prostate cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or less

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Negative controls of cell proliferation: human prostate cancer cells and androgens

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Establishment of two human prostate cancer cell lines derived from a single bone metastasis

25 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Testosterone replacement therapy following radical prostatectomy

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Intermittent androgen blockade should be regarded as standard therapy in prostate cancer.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer.

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

A single institution experience with biochemical recurrence after radical prostatectomy for tumors that on pathology are of small volume or “insignificant”

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4236330

Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy

2 December 2018

1 reference

12 December 2020

Is low serum free testosterone a marker for high grade prostate cancer?

1 reference

12 December 2020

The LNCaP cell line--a new model for studies on human prostatic carcinoma

1 reference

12 December 2020

Determination of cell number in monolayer cultures

1 reference

12 December 2020

Low serum testosterone and a younger age predict for a poor outcome in metastatic prostate cancer

1 reference

12 December 2020

Identifiers

DOI

10.4103/1008-682X.129132

1 reference

release_o5h46oqtibbznm6cbvzvmm6qi4

8 September 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/o5h46oqtibbznm6cbvzvmm6qi4

24 November 2022

mapped directly with Wikidata item

PMCID

4236330

1 reference

8 September 2017

1 reference

PMCID

4236330